Teva-MedinCell Alliance Heats Up With Second Phase III Trial Underway
Studies Begin For Proposed First Subcutaneous LAI Formulation Of Olanzapine
Teva’s partnership with MedinCell for long-acting injectable products, first penned a decade ago, is beginning to gather steam, as another candidate entered the clinic ahead of a potential first approval in the coming months.
You may also be interested in...
Teva has indicated an imminent launch after gaining a long-awaited FDA approval for the Uzedy long-acting injectable risperidone 505(b)(2) hybrid product on which the firm has partnered with MedinCell. Pricing information has also been revealed.
Spain’s Laboratorios Farmacéuticos Rovi has a firm date to remedy issues observed in its application for a hybrid version of risperidone, developed using Rovi’s proprietary ISM drug-release technology platform.
In an acquisition said by both US-based companies to be highly complementary, Azurity Pharmaceuticals has taken control of Slayback Pharma for an undisclosed fee.